Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors
🌟 Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 🌟
Gastrointestinal Tumor
Chinese biotech company CARsgen Therapeutics unveiled the latest data for its targeted Claudin18.2 autologous CAR-T cell candidate product, CT041, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This therapy is specifically designed for Claudin18.2-positive solid tumors, such as gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic cancer.
🔬 **About CT041**
CT041 (satricabtagene autoleucel, satri-cel) is a groundbreaking CAR-T cell therapy undergoing multiple clinical trials in both China and the United States. Since 2022, it has received RMAT designation and orphan drug status from the FDA, and PRIME designation from the EMA.
📊 **Clinical Trial Highlights**
Between March 2019 and January 2024, a total of 98 patients participated in the Phase 1 trial of CT041. The trial results indicated:
– **Safety**: The most common adverse events were hematologic toxicities related to lymphocyte depletion, with no dose-limiting toxicities or treatment-related deaths reported.
– **Efficacy**: The overall objective response rate (ORR) was 37.8%, and the disease control rate (DCR) was 75.5%. The median progression-free survival (PFS) was 4.4 months, and the median overall survival (OS) was 8.4 months.
For gastric cancer patients, the results were even more remarkable:
– **ORR**: 57.4%
– **DCR**: 83.0%
– **Median PFS**: 5.8 months
– **Median OS**: 9.7 months
🎯 **Future Outlook**
CT041 has demonstrated promising safety and highly encouraging efficacy in heavily pretreated Claudin18.2-positive advanced gastrointestinal cancer patients. This breakthrough brings new hope and treatment options for patients with gastrointestinal tumors.
Follow us for more updates on the latest medical breakthroughs! 💡🌐
Whatsapp：+8613717959070
Email: doctor.huang@globecancer.com
#MedicalBreakthrough #CancerTreatment #CAR_T #CT041 #GastricCancer #PancreaticCancer #CARsgenTherapeutics #ASCO2024 #MedicalAdvances #CARsgen
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements
🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬
Patient 1: 53-year-old Male
Gastric Cancer,
Pancreatic Cancer
Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.
Patient 2: 57-year-old Female
Gastric Cancer,
Pancreatic Cancer
Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.
🏆 CT041 Achievements 🏆
– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.
– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.
– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.
– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.
– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!
We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
doctor.huang@globecancer.com,
or WhatsApp+8613717959070
The Medical Department will contact you as soon as they receive the reports.
#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A significant breakthrough in Chinese solid tumor CAR-T therapy, resulting in complete remission for pancreatic cancer patients.
Chinese pharmaceutical company SciCoMed announced a significant breakthrough in treating metastatic pancreatic cancer with its independently developed CAR-T cell therapy targeting Claudin18.2, known as CT041. Pancreatic cancer, often termed the “king of cancers,” presents a significant challenge with low survival rates. However, CT041’s two representative cases have garnered attention: two patients with refractory pancreatic cancer, who failed multiple lines of treatment, received CT041 therapy. The results showcased a substantial reduction in tumor lesions and, in some cases, complete disappearance, offering a glimmer of hope for pancreatic cancer patients.
In the case of a 58-year-old female patient, lung metastases significantly decreased post CT041 treatment. Similarly, a 75-year-old female patient achieved complete remission by the fourth week post-treatment, maintaining remission to date. These successful cases validate the remarkable efficacy of CT041 for refractory pancreatic cancer, sparking interest and anticipation among international experts.
Moreover, CT041 has garnered recognition for its efficacy in the field of digestive system tumors. As the world’s first CAR-T cell therapy targeting Claudin18.2, it demonstrates promising prospects in treating digestive system tumors. Research data illustrates that among 37 patients, 83.3% experienced tumor regression, with an objective response rate of 48.6%. Additionally, CT041 displayed significant effectiveness in late-stage gastric and pancreatic cancer patients, offering hope for future treatments.
The rapid development of CAR-T therapy in China involves over 20 companies contributing significantly. CT041’s success signifies China’s progress toward becoming a global leader in CAR-T therapy. Moving forward, scientists will continue efforts to enhance efficacy and reduce side effects, providing a ray of hope for more late-stage cancer patients.